Mesalazina Doc (Mesalazine)

Mesalazine works by inhibiting the cyclooxygenase and lipoxygenase pathways within the colonic mucosa, which lowers the production of prostaglandins and leukotrienes—key mediators of inflammation. It also modulates immune cell activity, decreasing cytokine release and limiting leukocyte infiltration, thereby reducing local inflammation and promoting mucosal healing.

The appropriate dose of Mesalazina Doc is determined by the prescribing clinician based on the severity of disease, patient weight, and response to therapy. Dosage may be adjusted during treatment, and patients should follow the specific instructions provided by their healthcare professional.

Safety data for mesalazine in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss the risks and alternatives with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Mesalazina Doc. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Mesalazina Doc (mesalazine) is a first‑line aminosalicylate for mild to moderate ulcerative colitis, offering a topical anti‑inflammatory effect directly in the colon. Compared with sulfasalazine, mesalazine has fewer systemic side effects because it lacks the sulfapyridine moiety. Biologic agents such as infliximab target deeper immune pathways and are reserved for moderate‑to‑severe disease or when mesalazine is insufficient.

Mesalazina Doc should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid exposing it to extreme temperatures or humidity, which could affect its stability and efficacy.

Mesalazina Doc is formulated for rectal administration, typically as a suppository or enema. The product is inserted into the rectum according to the prescribing information, usually after bowel evacuation. Patients should follow the specific technique and timing advised by their healthcare provider to ensure optimal drug delivery to the colonic mucosa.

Serious adverse events, although rare, include severe allergic reactions such as anaphylaxis, myocarditis, pancreatitis, blood dyscrasias (e.g., neutropenia or agranulocytosis), hepatotoxicity, and interstitial nephritis. Patients should seek immediate medical attention if they experience symptoms like rash, fever, chest pain, jaundice, or sudden changes in urine output.

Mesalazina Doc should be avoided in individuals with known hypersensitivity to mesalazine, other aminosalicylates, or salicylate compounds. It is also contraindicated in patients with severe renal or hepatic impairment, and in those who have experienced serious adverse reactions to similar medications. Clinicians must evaluate each patient’s medical history before initiating therapy.